Futu News, December 22, this Wednesday $BIOHEART-B (02185.HK)$An announcement was issued. The company will issue 23.937 million shares, priced at HK$21.25 per share, and 500 shares per lot. It is expected to be listed on December 23.
During the public sale phase, Baixinan was subscribed about 1.52 times, and the final number of shares distributed to the public sale was 2.394 million shares, accounting for 10% of the total number of shares offered (before any over-allotment rights were exercised). A total of 1994 valid applications were received. The first-hand winning rate was 85%, and the second-hand subscription was stable.
Furthermore, the international offering was slightly oversubscribed. The final number of shares offered was 21.543 million shares, equivalent to 90% of the total number of shares offered (before any overallotment rights were exercised). Futu Information collates relevant data in the following table:
The net proceeds of approximately HK$442 million will be used for the following purposes: approximately 62% will be used to fund ongoing confirmatory clinical trials, preparation for registration and commercialization of the company's core product Bioheart®; approximately 21.3% to fund ongoing randomized controlled clinical trials in China and the ongoing development of the second-generation Iberis® product for renal nerve blocking; and approximately 6.7% will be used for R&D, ongoing preclinical studies and planned clinical trials of other products under development in the pipeline, including Bio-Leap™, Bioheart Ultra™, Bioheart® Balloon Dilation Catheter, Bioheart® Hyperbaric Balloon Dilation Catheter, Bioheart® Pulse Balloon Dilation Catheter...